Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
Daniela Paola Roggeri,1 Alessandro Roggeri,1 Elisa Rossi,2 Elisa Cinconze,2 Antonio Gasbarrini,3 PierAlessandro Monici Preti,4 Marisa De Rosa,2 1ProCure Solutions, Nembro, Bergamo, 2CINECA, Interuniversity Consortium, Bologna, 3Catholic University of Sacred Heart, Policlinic A Gemelli, Rome, 4Alfa W...
Guardado en:
Autores principales: | Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/adea37cfb71349919f42ef1982ce303b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri DP, et al.
Publicado: (2017) -
Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011) -
Accreditation program for gastrointestinal endoscopes reprocessing in Italy: An on-site survey
por: Giancarlo Spinzi, et al.
Publicado: (2021) -
Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup LS, et al.
Publicado: (2019) -
Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014)